secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001867096-25-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M
--------------------------------------------------------------------------------

- Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)
- Recorlev Q4 revenue $22.6M (+131% YoY); full-year $64.3M (+118% YoY)
- Q4 net loss $5.1M (($0.03)/share); Adjusted EBITDA $8.3M; cash $71.6M
- FY2025 revenue guidance $255M-$275M; expects positive Adjusted EBITDA going forward

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/0001867096-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/xers-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer